MRSN - Mersana Therapeutics, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Currency in USD

Valuation Measures

Market Cap (intraday) 5129.8M
Enterprise Value 310.74M
Trailing P/E N/A
Forward P/E 1-1.93
PEG Ratio (5 yr expected) 1N/A
Price/Sales (ttm)2.91
Price/Book (mrq)1.20
Enterprise Value/Revenue 30.24
Enterprise Value/EBITDA 6-0.31

Trading Information

Stock Price History

Beta (3Y Monthly) 1.34
52-Week Change 3-78.60%
S&P500 52-Week Change 3-0.33%
52 Week High 315.9300
52 Week Low 32.6500
50-Day Moving Average 33.6216
200-Day Moving Average 34.6541

Share Statistics

Avg Vol (3 month) 3243.31k
Avg Vol (10 day) 3137.57k
Shares Outstanding 522.9M
Float 24.7M
% Held by Insiders 1N/A
% Held by Institutions 1N/A
Shares Short (Jul 31, 2019) 4799.66k
Short Ratio (Jul 31, 2019) 45.06
Short % of Float (Jul 31, 2019) 43.38%
Short % of Shares Outstanding (Jul 31, 2019) 41.67%
Shares Short (prior month Jun 28, 2019) 41.27M

Dividends & Splits

Forward Annual Dividend Rate 4N/A
Forward Annual Dividend Yield 4N/A
Trailing Annual Dividend Rate 3N/A
Trailing Annual Dividend Yield 3N/A
5 Year Average Dividend Yield 4N/A
Payout Ratio 40.00%
Dividend Date 3N/A
Ex-Dividend Date 4N/A
Last Split Factor (new per old) 2N/A
Last Split Date 3N/A

Financial Highlights

Fiscal Year

Fiscal Year Ends Dec 31, 2018
Most Recent Quarter (mrq)Jun 30, 2019

Profitability

Profit Margin -77.78%
Operating Margin (ttm)-81.88%

Management Effectiveness

Return on Assets (ttm)-18.52%
Return on Equity (ttm)-44.97%

Income Statement

Revenue (ttm)44.58M
Revenue Per Share (ttm)1.43
Quarterly Revenue Growth (yoy)-95.20%
Gross Profit (ttm)-49.32M
EBITDA -35.15M
Net Income Avi to Common (ttm)-34.67M
Diluted EPS (ttm)-1.1160
Quarterly Earnings Growth (yoy)N/A

Balance Sheet

Total Cash (mrq)128.18M
Total Cash Per Share (mrq)2.68
Total Debt (mrq)9.11M
Total Debt/Equity (mrq)8.39
Current Ratio (mrq)5.50
Book Value Per Share (mrq)2.27

Cash Flow Statement

Operating Cash Flow (ttm)-65.26M
Levered Free Cash Flow (ttm)-25.99M